2022 C-Suite Summit Program Book

C-SUITE SUMMIT PROGRAM AGENDA

OCTOBER 18, 2022

7:30 a.m. – Registration & Networking Breakfast Buffet

8:15 a.m.

8:15 a.m. – Welcome & Opening Remarks
8:30 a.m.
• Will Lewis JD, MBA, Chair & CEO, Insmed & Chair, BioNJ
• Debbie Hart, President & CEO, BioNJ

8:30 a.m. – Keynote: Decoding the Future of the Life Sciences Industry

9:00 a.m. • Rajesh Parekh, Ph.D., Senior Partner, McKinsey & Company

9:00 a.m. – Panel: Shaping the Change
9:45 a.m. Panelists:

• Brad Bailey, Senior Vice President & General Manager, U.S., Genmab
• Greg Hersch, Ph.D., Senior Vice President & Head, Enterprise Strategy, Merck & Co.
• David Jiménez, President, Janssen Immunology, Janssen Pharmaceutical
Companies of Johnson & Johnson & Board Member, BioNJ
• Will Lewis, JD, MBA, Chair & CEO, Insmed & Chair, BioNJ
Moderator:
• Greg Graves, Partner, McKinsey & Company

9:45 a.m. – Fireside Chat: The Future of Work
10:15 a.m.
Interview with:
• Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK

Interviewer:
• Nitin Seth, CEO, Incedo

10:15 a.m. – Networking Break

10:30 a.m.

10:30 a.m. – Panel: Markets In Flux
11:15 a.m. Panelists:

• Chris Garabedian, CEO, Xontogeny & Venture Portfolio Manager, Perceptive Advisors
• Christopher Mortko, Ph.D., Associate Vice President & Head, HQ Search & Evaluation,
Merck Business Development & Licensing & Board Member, BioNJ
• Dennis Purcell, Founder, Aisling Capital
• Monika Vnuk, M.D., Managing Director, Blackstone Life Sciences
Moderator:
• Arda Ural, Ph.D., Americas Industry Markets Leader – Life Sciences & Healthcare, EY

1

www.BioNJ.org

C-SUITE SUMMIT PROGRAM AGENDA

OCTOBER 18, 2022

11:15 a.m. – Panel Discussion: The Clinical Trials Paradigm Shift
12:00 p.m. Panelists:

• Mariah Baltezegar, MBA, Vice President & Head, Peri- and Post-Approval Studies and
Real World Evidence Specialized Solutions, PPD (part of Thermo Fisher Scientific)
• Steven J. Bulera, Ph.D., DABT, Corporate Vice President & Global Head, Toxicology
Charles River Laboratories
• Terttu Haring, M.D, Head, Clinical Innovation Office, Sanofi
Moderator:
• Jackie Berman, Partner, Morgan Lewis

12:00 p.m. – Fireside Chat: Cell & Gene Therapy – An Opportunity for New Jersey
12:30 p.m. Interview with:

• Alan Moore, Chief Strategy Officer, Center for Breakthrough Medicines
• Brad Glover, Ph.D., Executive Vice President & Chief Operating Officer, Celularity
Interviewer:
• Sarah Eichenberger, Partner, Katten

12:30 p.m. – Networking Lunch

1:15 p.m.

1:15 p.m. – Panel: The Evolving Market Access Landscape
2:00 p.m. Panelists:

• Bradley Campbell, President & CEO, Amicus Therapeutics
• Jeff Henderson, Vice President & Head, Global Market Access, Reimbursement and Distribution,
Vectiv Bio
• Dorothy Hoffman, Senior Director, Market Access Policy Team Lead, Pfizer Biopharmaceuticals Group
• Keith White, Head, Global Market Access, Amylyx
Moderator:
• Tom Evegan, Principal, Strategy & Management Consulting, RSM US

2:00 p.m. – Panel: Next Generation Patient Experience
2:45 p.m. Panelists:

• Michael Braun, Senior Vice President, Immunology & Fibrosis, Bristol Myers Squibb
• Kevin Hagan, President & CEO, PAN Foundation
• Mary Frances Harmon, Senior Vice President, Corporation Relations, PTC Therapeutics
Moderator:
• Jim Greenwood, Senior Policy Advisor, Chair, Life Sciences Policy Practice, DLA Piper

2:45 p.m. – Closing Remarks
3:00 p.m.
• Debbie Hart, President & CEO, BioNJ
3:00 p.m. –
3:30 p.m. Networking Reception

www.BioNJ.org 2
4

THANK YOU TO OUR CONFERENCE PARTNER
THANK YOU TO OUR SPONSORS

®

3

www.BioNJ.org

SPEAKERS

Brad Bailey, Senior Vice President & General Manager, U.S., Genmab
Mr. Bailey is a healthcare industry veteran with more than 25 years of experience in the specialty biopharma and
oncology spaces. He brings that experience to Genmab, where he leads U.S. business. Mr. Bailey has overseen the
growth of Genmab in the U.S. to more than 475 employees in the last two years — all supporting Genmab’s goal
of transforming the lives of people with cancer and other serious diseases. He has built an experienced leadership
team across market access, marketing, medical affairs, business insights and analytics, government affairs/policy, and
Patient services, as well as critical enabling functions, including legal, HR, finance, compliance, communications, IT and
Patient advocacy.

Mariah Baltezegar, MBA, Vice President & Head, Peri- and Post-Approval Studies and Real World
Evidence Specialized Solutions, PPD, part of Thermo Fisher Scientific
Ms. Baltezegar is a member of Peri- and Post-Approval Studies (PPAS) executive team and is responsible for the
performance, growth and development of consumer health and specialized real-world evidence (RWE) study
solutions. In her current role, she has developed innovative solutions for hundreds of consumer health and RWE
studies, including strategies like digital enablement, decentralized studies (DCT), central principal investigator models
and other approaches that aim to reduce Patient and caregiver burden. Over the last 20 years, she has held various
positions of increasing responsibility across the PPD enterprise all with a strategic eye for efficiency through process
or technology, maximizing the study participant and site experience while ensuring high quality customer results.

Jackie Berman, Partner, Morgan Lewis
Ms. Berman advises companies throughout the U.S. Food and Drug Administration (FDA)-regulated
product supply chain on regulatory and compliance requirements. She helps clients navigate complex
issues associated with development, approval and commercialization of prescription and non-prescription
pharmaceuticals and biologics, including vaccines, and cell and gene therapies. Ms. Berman further counsels
clients on legal requirements under laws enforced by the U.S. Consumer Product Safety Commission, Federal
Trade Commission, U.S. Drug Enforcement Agency and state licensing agencies for consumer products,
controlled substances, pharmaceuticals and medical devices. Ms. Berman is an active member of the Food
and Drug Law Institute, having served on numerous committees over the years.

Michael Braun, Senior Vice President, Immunology & Fibrosis, Bristol Myers Squibb
Mr. Braun joined Bristol Myers Squibb in 2022 as Senior Vice President, U.S. Immunology and Fibrosis. In
this role, he is responsible for leading the strategy and full commercialization of the company’s offerings in
dermatology, rheumatology, gastroenterology and neurology, and serves as a member of the U.S. leadership
team. He joined Bristol Myers Squibb from Novartis, where he spent 19 years, most recently as Vice
President, Head of the Immunology, Hepatology & Dermatology Franchise.

Steven J. Bulera, Ph.D., DABT, Corporate Vice President & Global Head, Toxicology, Charles River Laboratories
Dr. Bulara has more than 25 years in the pharmaceutical industry and is currently Corporate Vice President,
Head of Scientific Oversight & Strategy and the Global Head of Toxicology for Safety Assessment at Charles
River Laboratories (CRL). Prior to joining CRL, Dr. Bulera held positions at Parke-Davis Pharmaceutical Research,
Pfizer Global Research & Development and Bristol Myers Squibb. Dr. Bulera holds degrees in biochemistry from
Canisius College (B.A.) and The University of Connecticut (M.S./Ph.D.). Dr. Bulera was a postdoctoral fellow in
the laboratory of Dr. Henry Pitot at the McArdle Laboratory for Cancer Research at the University of Wisconsin.
He is a Diplomate of the American Board of Toxicology.

Bradley Campbell, President & CEO, Amicus Therapeutics
Mr. Campbell joined Amicus in 2006 and has held various senior and executive roles throughout his tenure
at the company, including Vice President of Business Planning, Senior Vice President of Business Operations,
Chief Business Officer, and most recently serving as President and Chief Operating Officer from 2015 to 2022.
Mr. Campbell built and led the global organization responsible for the commercialization of Galafold® and
among his various roles has overseen the technical operations, Patient advocacy, market access, program
management, clinical operations and regulatory affairs functions. He currently serves on a number of boards,
including Gennao Bio, the Alliance for Regenerative Medicine and the Corporate Advisory Board for the
National Tay-Sachs and Allied Diseases Association.

www.BioNJ.org 4

SPEAKERS

Sarah Eichenberger, Partner, Katten
Ms. Eichenberger represents clients in high-stakes commercial litigation, including securities, class action and
shareholder derivative litigation, as well as in M&A matters. She also routinely counsels companies and boards
in connection with regulatory enforcement actions, internal investigations and cybersecurity incidents. Ms.
Eichenberger has handled matters for public and private companies across a range of industries, including
private equity, financial services, technology, energy, healthcare and aerospace and defense. Prior to joining
Katten, Ms. Eichenberger managed commercial litigation as an in-house attorney at Amazon.com, Inc., where
she oversaw the company’s response to securities and derivative litigation, as well as complex commercial
class actions.

Tom Evegan, Principal, Strategy & Management Consulting, RSM US
Mr. Evegan is a member of RSM’s life sciences leadership team, focused on helping companies with gross to
net, government pricing and commercial strategies and operations. With 20-plus years of experience in providing
services to companies in the pharmaceutical and biotechnology industries, he has worked with manufacturers
across brand, generic, specialty and device companies. As a skilled leader in the life sciences space, Mr. Evegan
has a history of working in the pharmaceutical industry to assist clients in developing commercial strategies, launch
products and help ensure market access and compliance. He currently has oversight for RSM’s revenue contract
management practice, with his primary focuses on biotechnology, government pricing, gross to net, M&A,
managed markets/market access, commercial operations and launch strategies.

Chris Garabedian, CEO, Xontogeny & Venture Portfolio Manager, Perceptive Advisors
Mr. Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early
development through clinical proof of concept. In 2017, Mr. Garabedian joined Perceptive Advisors to
develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund
which supports early stage companies with Series A investments across biotech, medtech and healthtech.
Prior, he served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the
turnaround of a company that is now a commercial stage leader in the genetic technology space after leading
the development of the company’s Duchenne Muscular Dystrophy program.

Brad Glover, Ph.D., Executive Vice President & Chief Technology Officer, Celularity
Mr. Glover is responsible for a clinically- and commercially-focused cell therapy and degenerative disease
products organization, managing all aspects of Global Program and Portfolio Management, Technical
Operations, Enterprise Facilities and Engineering, Human Resources, Strategic and Corporate Planning
and Enterprise IT. Prior to joining Celularity, he was at Kite Pharma where he held several executive roles
in Corporate Development and Technical Operations and was responsible for the strategic oversight and
leadership of corporate strategy, corporate program and portfolio management, technical operations
strategy, CMC program management, facilities and engineering and business operations. Previously,
Mr. Glover held several roles of increasing responsibility at Genentech and Roche.

Greg Graves, Partner, McKinsey & Company
Mr. Graves is one of the leaders of McKinsey’s pharmaceutical and medical products practice, focusing
on pharmaceutical launch, brand acceleration and the life sciences equipment/instrumentation industry.
Mr. Graves has served several innovative and generic pharmaceutical companies in the U.S. and Europe.
Mr. Graves has also served large life sciences technology companies focusing on instrumentation,
consumables and process design. He co-leads Mckinsey’s Life Science Interest Group and frequently advises
private equity clients on business development transactions in the life sciences space.

Jim Greenwood, Senior Policy Advisor, Chair, Life Sciences Policy Practice, DLA Piper
Mr. Greenwood advises clients on a variety of legislative, regulatory and policy issues impacting the healthcare
and life sciences sectors. Mr. Greenwood represented Pennsylvania’s Eighth Congressional District from 1993
to 2005. During his time in Congress, he was a senior member of the Energy and Commerce Committee and
widely viewed as a leader on healthcare and the environment. He crafted legislation to reform the Food and
Drug Administration, to create the pediatric exclusivity and pediatric autism research acts and he led the fight
in Congress to allow stem cell research to be conducted by U.S. scientists to treat disease. Prior to joining DLA
Piper, Mr. Greenwood served as President and CEO of BIO.

5

www.BioNJ.org

SPEAKERS

Kevin Hagan, President & CEO, PAN Foundation
Mr. Hagan leads the organization’s strategy and oversees its growing portfolio of financial assistance programs
and advocacy initiatives to expand healthcare access. He has over 25 years of executive leadership and
management experience in national and global non-profits, government and high-impact companies in the
private sector. Mr. Hagan previously served as CEO of Thrive Impact, a consulting firm he co-founded in 2018
that supports leadership teams at non-profits with organizational strategy, leadership and governance and
revenue diversification. Before founding Thrive Impact, he led the growth and transformation for several highly
respected non-profits, previously serving as CEO of the American Diabetes Association, President and CEO of
Feed the Children and Chief Operating Officer of Good360.

Terttu Haring, M.D., Head, Clinical Innovation Office, Sanofi
Within the Sanofi platform for Clinical Sciences & Operations, Dr. Haring leads a small team focused on
bringing innovative solutions and approaches to the portfolio of development projects. Dr. Haring has 20
years’ experience in clinical development in different roles, such as principal investigator in a clinical research
center, therapeutic director in a CRO, country and regional head for clinical study units in Sanofi and global
head for Trial Operations (including data management) in Sanofi. Dr. Haring graduated from Maastricht
University in the Netherlands as a Medical Doctor and spent several years in surgery and Ob/Gyn clinics
before joining the pharmaceutical clinical development ecosystem.

Mary Frances Harmon, Senior Vice President, Corporation Relations, PTC Therapeutics
Ms. Harmon is the Head of Corporate Relations at PTC Therapeutics, which includes corporate
communications, Patient engagement/advocacy and government affairs. As head of corporate relations, she
provides leadership to these teams to ensure that the development and execution of strategies fulfill the
purpose of PTC – extending life’s moments for Patients with rare diseases and their loved ones. Ms. Harmon
was recognized for her work supporting Patient families with the 2020 Heart of BioNJ Award. Prior to joining
PTC in 2015, she held a similar position at NPS Pharma in which she built both the Patient services and Patient
advocacy departments.

Debbie Hart, President & CEO, BioNJ
Ms. Hart worked alongside New Jersey’s biopharmaceutical industry leaders to establish BioNJ in 1994.
Dedicated to BioNJ’s mission to help our Members help Patients, Ms. Hart is recognized as a respected
thought leader and influential advocate. Under Ms. Hart’s leadership, BioNJ has become the trusted voice
of the life sciences industry in New Jersey – working directly with legislative leaders in both Trenton and
Washington D.C. to advance the life sciences industry, foster medical innovation and patient access while
ensuring health equity and healthcare affordability. Most recently, she was named by Governor Murphy as
the Chair of the New Jersey Commission on Science, Innovation and Technology.

Jeff Henderson, Vice President & Head, Global Market Access, Reimbursement and Distribution, Vectiv Bio
Mr. Henderson has more than 31 years of pharmaceutical and biopharmaceutical experience. In his
current position, Mr. Henderson is responsible for global market access and encompasses payer account
management, payer strategy and marketing, trade and distribution, Patient services, field reimbursement,
pricing and government policy. Prior to joining VectivBio, Mr. Henderson held various executive level
leadership positions at Sobi, Intarcia Therapeutics, Vertex Pharmaceuticals and Pfizer. He has a broad range
of experience and expertise leading commercial teams within the industry and specializes in new product
commercialization, national and key account management, Patient services, rare diseases, marketing, trade
and distribution, specialty pharmacy, strategic planning and pharmaceutical contract negotiation and pricing.

Greg Hersch, Ph.D., Senior Vice President & Head, Enterprise Strategy, Merck & Co.
Dr. Hersch facilitates strategic development and planning efforts across the company with responsibility
for developing and executing on an integrated enterprise-wide strategy, with a focus on accelerating
simplification and digital efforts. Dr. Hersch leads the enterprise strategy team, promoting strong
collaboration across the enterprise to enable the development of a unified strategic approach, as one team,
driving the strategic actions necessary to prepare Merck for future success. He joined Merck from Novartis
where he was Digital Program Head within Novartis’ Global Drug Development organization and was
responsible for the development and implementation of enterprise-wide digital transformation initiatives.

www.BioNJ.org 6

SPEAKERS

Dorothy Hoffman, Senior Director, Market Access Policy Team Lead, Pfizer Biopharmaceuticals Group
Ms. Hoffman serves as Market Access Policy Lead and is a member of the leadership team of Pfizer’s
Healthcare Innovation Center. Pfizer’s Healthcare Innovation Center is responsible for co-creating partnerships
and collaborations that improve the Patient experience, access and affordability, while also addressing the
needs of payers and providers. Prior to joining Pfizer, Ms. Hoffman was Vice President of Prescription Drug
Policy at UnitedHealth Group.

David Jiménez, President, Janssen Immunology, Janssen Pharmaceutical Companies of Johnson & Johnson
and Board Member, BioNJ
Mr. Jiménez has held numerous commercial, strategic and leadership positions in both mature and emerging
markets across the world. In his role as President, Janssen Immunology, Mr. Jiménez leads the growing $10+
billion U.S. Immunology franchise, home to many of the most transformational brands in the pharmaceutical
industry, including STELARA®, TREMFYA®, SIMPONI ARIA® and REMICADE®. Focused on rheumatology,
dermatology and gastroenterology, Mr. Jiménez and his team aspire to relentlessly advance care for Patients
living with immune-mediated disease through medical innovation and enhancing the Patient experience.

Will Lewis JD, MBA, Chair & CEO, Insmed & Board Chair, BioNJ
Mr. Lewis joined Insmed in 2012 as President and CEO and as a member of the board of directors. He
became Chair of the Board of Directors in November 2018. Mr. Lewis is the former Co-Founder, President and
Chief Financial Officer of Aegerion Pharmaceuticals, Inc., and previously spent more than 10 years working
in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Mr. Lewis
serves as the Chair of the Board of Trustees of BioNJ, is a member of the Board of Trustees of Case Western
Reserve University and serves as a member of the Board of the Helix Acquisition Corp.

Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK
Ms. Martinez-Davis joined GSK in 2019 and leads a thriving organization of more than 10,000 professionals,
focused on uniting science, talent and technology to get ahead of disease together. Ms. Martinez-Davis
also heads a vibrant and complex business portfolio of products in specialty, respiratory (including COVID
therapeutics), oncology and vaccines. She is steadfast in her belief that it is GSK’s obligation to deliver
differentiated, high-quality medicines and vaccines to the many Patients and communities in need. She is a
demonstrated global leader and influencer in the life sciences commercial field with a passion for U.S., global
and emerging markets.

Alan Moore, Chief Strategy Officer, Center for Breakthrough Medicines
Mr. Moore has over 40 years of experience in the life sciences contract services field and most recently
served as Vice President and Head of Strategic Alliances at WuXi Advanced Therapies. He was responsible
for developing and maintaining strategic manufacturing relationships for autologous, allogeneic and gene-
mediated cell and gene therapies, and strategic partnering in biologics services. Prior to WuXi, Mr. Moore
served as Executive Vice President and Chief Business Officer at Althea Technologies following his tenure
at Genzyme where he held a Senior Regulatory Coordinator and Vice President of Biopharm Development
Services position.

Christopher Mortko, Ph.D., Associate Vice President & Head, HQ Search & Evaluation
Merck Business Development & Licensing & Board Member, BioNJ
Dr. Mortko leads a team responsible for the search, scientific evaluation and due diligence for late-stage
research and development opportunities across all therapeutic areas and enabling technologies. He is a key
member of Merck’s Science, Strategy and Business review governance committee that is responsible for
decision making and deal structure/terms for business development opportunities. Prior to joining Merck
Business Development, Dr. Mortko was a Senior Biotechnology Equity Analyst on Wall Street, focusing on
oncology, immunology and other therapeutic areas. Earlier in his career, he was a research scientist at Amgen
and Merck and was involved in drug discovery and development across therapeutic areas.

7

www.BioNJ.org

SPEAKERS

Rajesh Parekh, Ph.D., Senior Partner, McKinsey & Company
Dr. Parekh leads McKinsey’s Life Sciences Practice. He has supported companies across the healthcare sector
on topics such as growth strategy, business building, market access and R&D. Since joining McKinsey in
1996, following completion of a Ph.D. in chemical engineering, Dr. Parekh’s clients have included leading
pharmaceutical and medical-device companies, insurance companies, distributors and private-equity
investors. In addition to his work with corporate clients, Dr. Parekh helped lead McKinsey’s work with a major
regional government on healthcare reform and has worked with leading industry associations to develop
perspectives and strategies in the face of a changing regulatory environment.

Dennis Purcell, Founder, Aisling Capital
Mr. Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing
Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment
Banking Group at Chase H&Q for over five years. While at H&Q, he was directly involved with over two
hundred completed transactions and supervised over $10 billion of financing and advisory assignments in
the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other
industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q,
Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Nitin Seth, CEO, Incedo
Mr. Seth is an accomplished technology industry leader, a global manager, innovative entrepreneur,
management consultant and best-selling author. He is the CEO of Incedo Inc., a high-growth Digital, Data
and Analytics firm, and has held top management positions at McKinsey, Fidelity International and Flipkart.
Mr. Seth is the author of the bestselling book “Winning In The Digital Age”, that has won four Best Business
Book awards, including BBLF CK Prahalad 2022, International Business Awards, American Business Awards
and Axiom. He holds an MBA from the Indian Institute of Management, Lucknow, and a B. Tech from the
Indian Institute of Technology, Delhi.

Arda Ural, Ph.D., Americas Industry Markets Leader – Life Sciences & Healthcare, EY
Prior to joining EY, Dr. Ural was a Managing Director at a strategy consulting firm for six years where he
led the Life Sciences M&A Practice. Earlier, Dr. Ural worked as a Vice President of Strategic Marketing and
a BU Lead at an American medical technology company. He also served as the Senior Vice President of
Marketing & Sales for a start-up biotechnology company which went public. Dr. Ural started his career with a
pharmaceutical company in Istanbul and subsequently relocated to New York, where he held leadership roles
in product commercialization and new product development.

Monika Vnuk, M.D., Managing Director, Blackstone Life Sciences
Before joining Blackstone, Dr. Vnuk worked at Pfizer where she was Vice President of Worldwide Business
Development. While at Pfizer, Dr. Vnuk negotiated the Pfizer-BioNTech collaboration which resulted in the
successful development of a vaccine against COVID-19. Prior to Pfizer, Dr. Vnuk was a Vice President at Banc
of America Securities and a Principal at Oxford Bioscience Partners, a venture capital firm focused on early
stage biotechnology investments.

Keith White, Head, Global Market Access, Amylyx
Before joining Amylyx Pharmaceuticals, Mr. White was Vice President, Market Access at Intercept
Pharmaceuticals where he led U.S. payer relations, pricing, HEOR, channel/distribution, reimbursement
and Patient services functions for their lead product Ocaliva. Prior to that, he held commercial leadership
positions at InterMune and was the U.S. Head, Market Access, Reimbursement and Strategic Accounts at
ThromboGenics where he was responsible for the U.S. launch of JETREA. Mr. White also spent 14 years at
Genentech in various commercial leadership roles, including sales, marketing, managed care marketing,
contract strategy, commercial and public account management, government affairs and strategic leadership.

www.BioNJ.org 8
180

CONFERENCE SPONSOR

McKinsey & Company is a global management consulting firm that seeks to help
clients realize their most important goals. In biopharma, McKinsey provides specialized
capabilities that focus on the needs of small- and mid-cap companies in clinical and early
commercialization stages, including TA and clinical strategy, medical, regulatory and
market access.

CEO SPONSORS

As scientific progress, augmented intelligence and digital data are transforming the
traditional healthcare models, staying competitive and providing the personalized
experience that Patients demand, require life sciences organizations to find new ways of
working. EY Life Sciences works with pharma, biotech and medical technology companies
to help shape our clients’ data-driven innovation approach and sustainable business
outcomes, leveraging our powerful technology alliances. Every day, our life sciences
and health professionals deploy their vast knowledge to execute organic and inorganic
growth strategy, supply chain, technology transformation, commercialization, R&D and
talent strategy. A healthy world is a better working world.

RSM’s purpose is to deliver the power of being understood to our clients, colleagues
and communities through world-class audit, tax and consulting services focused on
middle market businesses. The clients we serve are the engine of global commerce and
economic growth, and we are focused on developing leading professionals and services
to meet their evolving needs in today’s ever-changing business environment. RSM US LLP
is the U.S. member of RSM International, a global network of independent audit, tax and
consulting firms with 51,000 people across 123 countries. Like us on Facebook, follow us
on Twitter and/or connect with us on LinkedIn.

PRESIDENT SPONSORS

DLA Piper is a global law firm with lawyers located in more than 40 countries throughout
the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help
clients with their legal needs around the world. We strive to be the leading global
business law firm by delivering quality and value to our clients. We achieve this
through practical and innovative legal solutions that help our clients succeed. We
deliver consistent services across our platform of practices and sectors in all matters
we undertake. Our clients, among them life sciences clients, range from multinational,
Global 1000 and Fortune 500 enterprises to emerging companies developing industry-
leading technologies. We also advise governments and public sector bodies. For more
information, contact Emilio Ragosa at [email protected].

Katten is a full-service international law firm that specializes in defending life-sciences
clients in “bet the company” securities fraud litigation, stockholder derivative suits and
competitor unfair competition actions. Our internationally recognized practices include
Litigation, Intellectual Property, Corporate, Transactional Tax Planning, Commercial
Finance, Financial Markets and Funds, Insolvency and Restructuring, Private Wealth,
Real Estate and Structured Finance and Securitization. Our dynamic team of almost 700
attorneys seamlessly operates from 10 locations across the United States, the United
Kingdom and China.

9

www.BioNJ.org

PRESIDENT SPONSORS (CONT.)

With 400 international partners and counsel who focus on the life sciences industry,
Morgan Lewis has one of the most comprehensive practices in New Jersey and
around the world. We are unsurpassed in our global understanding of the business,
regulatory, intellectual property, litigation and related issues that our clients face along
the product life cycle, from innovation and emerging business issues, through research and
development, regulatory approval, product reimbursement, marketing and distribution,
to fraud and abuse, product liability and intellectual property litigation, to mergers and
acquisitions, collaborations and outsourcing. The breadth of our industry clientele includes
large and mid-size pharma and biopharma, emerging biotechnology, medical device, food
and nutritional supplements, wholesalers and distributors, research and scientific
institutions and venture capital and private equity funds focused on the industry.

EXECUTIVE SPONSORS

Incedo, a global Digital Transformation expert providing consulting, analytics and
technology services, works with leading life sciences and healthcare companies to
deliver transformative and innovative solutions leveraging Data, AI and Cloud across
the clinical and commercial value chains. Incedo helps our customers achieve a
sustainable business advantage by bridging the gap between business and technology
bringing together strong engineering, data science and design capabilities with deep
domain understanding. Incedo blurs the boundaries between services and products to
maximize business impact from emerging technologies.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform
the lives of Patients with serious and rare diseases. Insmed’s first commercial product
is a first-in-disease therapy approved in the United States, Europe and Japan. The
company is also progressing a robust pipeline of investigational therapies targeting
areas of serious unmet need, including neutrophil-mediated inflammatory diseases and
rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a
footprint across Europe and in Japan.

BOARD SPONSORS

Amicus Therapeutics (Nasdaq: FOLD) is a global, Patient-dedicated biotechnology
company focused on discovering, developing and delivering high-quality medicines
for people living with rare metabolic diseases.

Faegre Drinker’s Health & Life Sciences Industry Team is built from our interdisciplinary
practice groups, comprised of attorneys who have experience, knowledge and insights
about navigating this fast-paced, heavily regulated environment. We can support you
through scientific research, life sciences product development, intellectual property
protection, employment issues and litigation, product marketing and sales, healthcare
delivery and more. Whether you’re facing issues relating to business and financing
pressures, regulatory scrutiny, workforce management or litigation threats, we stand
ready to provide collaborative and strategic advice. We value the opportunity to partner
with clients to advance your business and legal needs.

www.BioNJ.org 10

BOARD SPONSORS (CONT.)

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of
more than $40 billion and approximately 100,000 employees globally. Our mission
is to enable our customers to make the world healthier, cleaner and safer. We help
our customers accelerate life sciences research, solve complex analytical challenges,
improve Patient diagnostics, deliver medicines to market and increase laboratory
productivity. For more information, please contact Kristin Roosevelt at
[email protected], or 610-453-0370.

Herspiegel Consulting is a leading provider of commercialization services to
pharmaceutical and biotech companies. Our services include new product planning,
product launch preparation, commercial strategy and marketing excellence, medical
affairs and market access strategy with expertise across a wide variety of therapeutic
areas. We help our clients define impactful strategic approaches, commercialization
processes, enhance business intelligence and optimize product launch performance.
With our team of dedicated experts, Herspiegel Consulting has the skills to solve
your critical business issues, create innovative solutions and develop best-in-class
deliverables that optimize the value of your brands. Please contact Brent Herspiegel
at [email protected] or 609-977-4797.

Marcum LLP has audit, tax and advisory professionals dedicated to serving the
needs of the life sciences and biotech industries. From development stage start-ups
to revenue-generating accelerated public company filers, Marcum has the breadth
of experience to deal with the challenges companies face. We have decades of
experience serving clients involved with raising capital, investor exits, complex revenue
recognition, equity compensation, international expansion, reliance on intellectual
property, mergers and acquisitions, initial public offerings and uplift strategies.

Marsh and Mercer are part of Marsh McLennan, the world’s leading professional
services firm in the areas of risk, strategy and people. We are global businesses
united by a common purpose and a uniquely collaborative culture. Our 76,000
colleagues advise organizations in over 130 countries, helping them navigate an
increasingly dynamic and complex environment. We are committed to each other,
to our clients and to the greater good. Every day, we help clients change what’s
possible, enabling enterprise around the world, through our businesses.
Marsh – Risk & Insurance Services Consulting: Insurance Broking & Risk Management
Mercer – Health, Wealth & Career Consulting

TriNet provides small- and medium-size businesses (SMBs) with full-service HR
solutions tailored by industry. To free SMBs from HR complexities, TriNet offers
access to human capital expertise, benefits, risk mitigation and compliance and
payroll, all enabled by industry leading technology capabilities. TriNet’s suite of
products also includes services and software-based solutions to help streamline
workflows by connecting HR, benefits, employee engagement, payroll and time and
attendance. From Main Street to Wall Street, TriNet empowers SMBs to focus on what
matters most — growing their business and enabling their people. TriNet, incredible
starts here.

11

www.BioNJ.org

ATTENDEE LIST List as of 10/17/22 11A.M.

First Name Last Name Title Company
Corey Ackerman Senior Partner Cornerstone Search Group, LLC
Roger Adsett Chief Operating Officer Insmed Incorporated
Susana Agrusti Relationship Manager Mercer Health & Benefits LLC
Al Altomari President & CEO Agile Therapeutics, Inc.
Robert Azzara Vice President, Human Resources BeyondSpring Pharma
Brad Bailey Senior Vice President, General Manager, US Genmab
Mariah Baltezegar, MBA VP and Head, Peri- and Post-approval Studies and PPD
Samantha Bamberger Exec. Dir., BioPartnering Conference & Committees BioNJ
Jacqueline Berman Partner Morgan Lewis
Susan Blum Chief Financial Officer Melinta Therapeutics
Brion Brandes VP, Commercial Solutions Incedo
Michael Braun Senior VP, Immunology & Fibrosis Bristol-Myers Squibb Company
Mike Breggar Senior Director RSM US LLP
Dan Brettler Senior Partner Conner Strong & Buckelew
Randi Bromberg Vice President, Communications & Marketing BioNJ
Steven Bulera, PhD, DABT Corporate VP, Global Head of Toxicology Charles River Laboratories
Thomas Burke Associate Morgan, Lewis & Bockius
Brett Busconi VP, Client Development Javan Engineering
Paul Calamita Partner RSM US LLP
Bradley Campbell President and CEO Amicus Therapeutics, Inc.
James Campolongo Head, State Government Affairs GSK
Thomas Cantwell Partner Marcum LLP
Quinn Caswell Supervisor RSM US LLP
Juliet Chin-Hart Principal Hart & Chin Associates, LLC
Sean Clements Business Unit Communications Leader Janssen Pharmaceuticals
Caitlin Craparo Senior Director, US Market Communications Genmab
Anthony Dalonges Manager RSM US LLP
Jennifer Daugherty Global Enterprise Relationship Lead Fisher Scientific
Maryalice DeCamp Managing Director EY US LLP
Matt DeLeonardis Strategic Account Executive WhizAI
William DeStefano VP, Life Science Practice Marsh Inc.
Annie Devine Senior Vice President Marsh
Sahar Dhaher Project Manager CRB
Pat Duffy Director, NJ Office Lead CRB
Sarah Eichenberger Partner Katten Muchin Rosenman LLP
Tom Evegan Principal, Strategy & Management Consulting RSM US LLP
Emmie Fan Chief Business Officer Avotres Inc.
Robert Fiorentino, CPA Life Science Practice Lead Partner Marcum LLP
Charley Ford Senior Commercial Officer Chinese Consulate General in New York - Ontario Trade &
Investment
Kelley Ford VP, Manufacturing and Supply, Technical Ops. Suppl Melinta Therapeutics
Chris Garabedian Portfolio Manager - Venture Perceptive Advisors
Jayne Gershkowitz Chief Patient Advocate Amicus Therapeutics, Inc.
Nechumah Getz Chief Strategy and Operations Officer PAN Foundation

www.BioNJ.org 12

ATTENDEE LIST List as of 10/17/22 11A.M.

First Name Last Name Title Company
Debjit Ghosh Director- Life Sciences Solutions Incedo, Inc.
Doug Girgenti Vice President, Head of Development Melinta Therapeutics
Bradley Glover, PhD Executive VP, Chief Operating Officer Celularity Inc.
Amanda Goceljak Partner Morgan Lewis
Tom Gordon Managing Director Silicon Valley Bank
David Granese Chief Financial Officer Vitalief Inc.
Greg Graves Partner McKinsey & Company
Marisa Greenwald Principal EY US LLP
Jim Greenwood Senior Policy Advisor DLA Piper
Jim Gunton Managing Partner Tech Council Ventures
Ashish Gupta SVP and Head, Data & AI Incedo, Inc.
Michael Hadjiloucas Partner EisnerAmper
Kevin Hagan President & CEO Pan Foundation
Terttu Haring, MD Head, Clinical Innovation Office Sanofi US
John Harlow Chief Commercial Officer Melinta Therapeutics
Mary Frances Harmon Senior Vice President, Corporate Relations PTC Therapeutics, Inc.
Kevin Harris Chief Commercial Officer VectivBio
Debbie Hart President & CEO BioNJ
Jeff Henderson VP, Head of Global Market Access, Reimb. & Distr. Vectiv Bio
Cheri Hennessy Executive Director, Strategic Partnerships BioNJ, Inc.
Gregory Hersch, PhD Senior VP, Head of Enterprise Strategy Merck & Co., Inc.
Brent Herspiegel President Herspiegel Consulting LLC
Dorothy Hoffman Senior Director, Market Access Policy Team Lead Pfizer Inc.
Harvey Homan CEO and Co-Founder MetasTx, LLC
John Houghton President & CEO Avotres Inc.
Pavita Howe Assistant Director, Commercialization Funding Rutgers University
Korey Inglin Associate Morgan Lewis
Jerome Jabbour, PhD CEO Matinas BioPharma
Jay Jackson Partner, Market Access Herspiegel Consulting LLC
David Jimenez President, Janssen Immunology Janssen Pharmaceuticals
Judy Johnson Managing Director, Organizational Effectiveness Aspirant
Lou Kassa Chief Executive Officer PA Biotechnology Center/Blumberg Institute/Hepatitis B
Foundation
Christopher Kiesel Client Services Manager BioBridges
Mark Kolb Entrepreneur in Residence Tech Council Ventures
Paul Korner Chief Medical Officer Agile Therapeutics, Inc
Kate Kozak Industry Director of Sales - Life Sciences TriNet
Harish Kumar Associate Director EY US LLP
Walter Lane Director of Planning, Policy and Eco. Develop Somerset County Office of Planning, Policy and Economic
Development
Jon Lange Principal EY US LLP
Wendy Lazarus Principal WML Public Affairs
Gary Lee Executive Director, Corporate Development Amicus Therapeutics, Inc.
Jack Levitt Co-Founder & Principal LeaderStrong
Will Lewis, JD, MBA Chair & CEO Insmed Incorporated

13

www.BioNJ.org

ATTENDEE LIST List as of 10/17/22 11A.M.

First Name Last Name Title Company
Jordan Lovett Senior Director of Business Development WuXi AppTec
Denise Machado Manager, Membership Operations BioNJ
Eugene Mancino Partner Mancino Burfield Edgerton
Kevin Mange SVP, Clinical Deveopment Insmed
Adam Marshall Partner RSM US LLP
Maya Martinez-Davis President, US Pharmaceuticals GSK
Chris Masi Vice President Jones Lang LaSalle
Theresa Matkovits, PhD Chief Development Officer Matinas BioPharma
Michael McInerney Executive Director, BD Digital Health Bristol Myers Squibb Company
Ian McLaughlin, PhD Executive Director, Public Affairs BioNJ, Inc.
Marisol Mendez Peron Sr Vice President, Communications & Corp Affairs Genmab
Debbie Mennito Executive Director, Talent Services & Events BioNJ
Isaac Millar Senior Manager EY
Christine Ann Miller President & CEO Melinta Therapeutics
Kim Minton Executive Director of Member Engagement BioNJ
Ann Mohamadi Managing Director - Health Advisory PricewaterhouseCoopers, LLP
David Moore CEO Vitalief
David Moore Chief Executive Officer Vitalief Inc.
Alan Moore Chief Strategy Officer The Center for Breakthrough Medicines
Kara Moore Sector Lead, Life Sciences New Jersey Economic Development Authority (NJEDA)
John Morel Senior Vice President Marsh USA
Chris Mortko, PhD, MBA Associate VP, Head of HQ Search & Evaluation Merck & Co., Inc.
Beth Ann Murphy Assistant Professor-PSM Program Rutgers
Santosh Naik Principal Herspiegel Consulting LLC
Lisa Nair VP, Quality Assurance Insmed
Kelsey Nakamura SVP Jones Lang LaSalle
Robert Neusner Global Director, Precision Medicine Johnson & Johnson (Janssen)
Lieven Nuyttens Founder and Principal Tri-Medix
Gregory Oakes President & CEO Landos Biopharma
Jessica Paolini Manager of Economic Development Somerset County Office of Planning, Policy and Economic
Development
Rajesh Parekh, PhD Senior Partner McKinsey & Company
Toral Patel Leader, External & Organizational Engagement & C Janssen Global Services, LLC
Alex Pawluk Executive Director, Clinical Quality Assurance Insmed
John Pennett, CPA Partner - Technology & Life Sciences EisnerAmper
Michele Pericci Sr. Director, Pricing and Contracting SCILEX Pharmaceuticals Inc.
Dawn Piccioni Marketing Manager BioNJ, Inc.
Peter Piliero VP, Medical Affairs Melinta Therapeutics
Tara Plastock Director of Sales TriNet
Alyssa Pogue Business Development Thermo Fisher Scientific Inc. - PPD
Cheri Potts Office Manager BioNJ
Dennis Purcell Senior Managing Partner Aisling Capital
Navneet Puri, PhD Founder, Chairman & CEO Nevakar, Inc.
Lori Rabinowitz SVP Morgan Stanley

14

www.BioNJ.org

ATTENDEE LIST List as of 10/17/22 11A.M.

First Name Last Name Title Company
Ravi Raghunathan, CPA Partner CohnReznick LLP
Aravind Ramamurthy SVP LIfe Sciences Incedo, Inc.
Srikant (Sri) Ramaswami Vice President, Head of Commercial Communications GSK
Steven Raz CEO, Co-Founder & Managing Partner Cornerstone Search Group, LLC
Mike Reagan SVP CGI
James Reynolds Principal Marcum LLP
Kristin Roosevelt Industry Director Fisher Scientific Company LLC
Alan Rubino Executive Chairman AMO Pharma Ltd.
Laura Ruth Senior Sales Consultant - Life Sciences TriNet
Barbara Ryan Senior Advisor EY
Dana Sacco Executive Assistant BioNJ
Matthew Scaliti Partner RSM US LLP
Chris Schaber, PhD President & CEO Soligenix, Inc.
Michael Schetlick Managing Director Centri Business Consulting
Eduardo Schur Partner EY
David Schwartz Partner Morgan Lewis
Nitin Seth Chief Executive Officer Incedo, Inc.
Anjali Shah Exec Director, Market Access Bayer Pharmaceuticals, USA
Scott Shields President & CEO Control Associates, Inc.
Natalina Smith Sales Manager Fisher Scientific Company LLC
Mark Solak Principal EY
Ryan Starkes Partner Centri Business Consulting
Art Telfeian Sales Director Coriell Institute for Medical Research
John Tomtishen VP of Operations Cellares Corporation
Raul Trillo Chief Commercial Officer Nevakar, Inc.
Tracy Tyler CEO Strategies for Success Int'l
John Underfer President Worldwide IP Solutions LLC
Arda Ural, PhD Partner EY
Lee Van Horn Partner EY
Alain Van Loo Founder Assetive
Swami Venkat Partner CohnReznick LLP
Monika Vnuk, MD Managing Director Blackstone Life Sciences
Joel Wagner Partner EY
Amy Welsh VP Marketing Agile Therapeutics, Inc.
Thomas Wescott, MSM Director, U.S. Business Development MMR Consulting USA Inc.
Keith White Head of Global Market Access Amylyx Pharma
Heather White Director Business Development The Center for Breakthrough Medicines
Ann Wieczkowski Manager, Accounting Services BioNJ
Dennis Wilson President & CEO Delta Dental of New Jersey and Connecticut
Joe Wolfe Business Development Director RSM
Rong Yang CEO Fosun Pharma USA Inc.
Tammy Zeoli Director, Business Development RSM US LLP
Jason Zimmerman Partner CohnReznick

15

www.BioNJ.org

Sincere Thanks to Our
BioNJ C-Suite Summit Committee Members

Arda Ural, Ph.D., MSc, MBA, EY – Chair Fa Liu, Ph.D., Focus-X Therapeutics, Inc.
Marc Beaver, BioBridges Marci Newnham, BioBridges
Dawn Bell, PharmD, Novartis Jisoo Park, Melinta Therapeutics
Robert Bloder, Ascendia Pharma John Pennett, CPA, EisnerAmper LLP
Brion Brandes, Incedo Peter Pfeiffer, Ph.D., McKinsey & Company
Brett Busconi, Javan Engineering Ravi Raghunathan, CPA, CohnReznick LLP
Marshall Calman, MBA, LeaderStrong Sri Ramaswami, GSK
Jan Campbell, MBA, Korn Ferry International Kristin Roosevelt, Thermo Fisher Scientific
Mitzi Conners, Merck & Co. Tony Torrington, CPA, EY
Raul Trillo, M.D., MBA, Nevakar
Manya Deehr, JD Alain Van Loo, Assetive
Emmie Fan, Avotres Rohit Vashist, WhizAI
Emma Kemble, McKinsey & Company Sitaram Velaga, Ph.D., Kenox Pharmaceuticals
Adam Knepp, Ph.D., McKinsey & Company Brian Wilcomes, CPA, Deloitte
Paul Korner, M.D., MBA, Agile Therapeutics Joe Wolfe, RSM US LLP
Jack Levitt, MBA, EMTM, LeaderStrong

Debbie Hart BioNJ Team Cheri Potts
Samantha Bamberger Dana Sacco
Denise Machado Peggy Schell
Randi Bromberg Ian McLaughlin, Ph.D. Ann Wieczkowski
Donna Gibbons
Cheri Hennessy Debbie Mennito
Kim Minton

Dawn Piccioni

Whitehorse Executive Center • 1255 Whitehorse-Mercerville Road
Building B, Suite 514 • Trenton, NJ 08619

609-890-3185 • [email protected] • www.BioNJ.org